Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches
Derek Kellar, Suzanne Craft
The Lancet Neurology (2020) Vol. 19, Iss. 9, pp. 758-766
Open Access | Times Cited: 584

Showing 1-25 of 584 citing articles:

Association Between Age at Diabetes Onset and Subsequent Risk of Dementia
Claudio Barbiellini Amidei, Aurore Fayossé, Julien Dumurgier, et al.
JAMA (2021) Vol. 325, Iss. 16, pp. 1640-1640
Open Access | Times Cited: 241
Western diet as a trigger of Alzheimer’s disease: From metabolic syndrome and systemic inflammation to neuroinflammation and neurodegeneration
Angelika Więckowska‐Gacek, Anna Mietelska‐Porowska, Małgorzata Wydrych, et al.
Ageing Research Reviews (2021) Vol. 70, pp. 101397-101397
Open Access | Times Cited: 237
Insulin and Insulin Resistance in Alzheimer’s Disease
Aleksandra Sędzikowska, Leszek Szablewski
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 9987-9987
Open Access | Times Cited: 215
Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise
Fei Yin
FEBS Journal (2022) Vol. 290, Iss. 6, pp. 1420-1453
Open Access | Times Cited: 182
Astrocytes as Key Regulators of Brain Energy Metabolism: New Therapeutic Perspectives
Elidie Béard, Sylvain Lengacher, Sara Dias, et al.
Frontiers in Physiology (2022) Vol. 12
Open Access | Times Cited: 167
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases
Rosalía Fernández‐Calle, Sabine C. Konings, Javier Frontiñán-Rubio, et al.
Molecular Neurodegeneration (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 136
MicroRNAs in Alzheimer's disease: Potential diagnostic markers and therapeutic targets
Sen Liu, Min Fan, Qiang Zheng, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 148, pp. 112681-112681
Open Access | Times Cited: 124
Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies
Jifa Zhang, Yinglu Zhang, Jiaxing Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 114
Intranasal Insulin for Alzheimer’s Disease
Manfred Hallschmid
CNS Drugs (2021) Vol. 35, Iss. 1, pp. 21-37
Open Access | Times Cited: 109
Recent Advances in the Modeling of Alzheimer’s Disease
Hiroki Sasaguri, Shoko Hashimoto, Naoto Watamura, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 108
The Immunopathogenesis of Alzheimer’s Disease Is Related to the Composition of Gut Microbiota
Friedrich Leblhuber, Daniela Ehrlich, Kostja Steiner, et al.
Nutrients (2021) Vol. 13, Iss. 2, pp. 361-361
Open Access | Times Cited: 105
Type 2 diabetes mellitus-associated cognitive dysfunction: Advances in potential mechanisms and therapies
Ailin Luo, Zheng Xie, Yue Wang, et al.
Neuroscience & Biobehavioral Reviews (2022) Vol. 137, pp. 104642-104642
Closed Access | Times Cited: 82
Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease
Marzia Perluigi, Fabio Di Domenico, D. Allan Butterfield
Physiological Reviews (2023) Vol. 104, Iss. 1, pp. 103-197
Closed Access | Times Cited: 71
GLP-1a: Going beyond Traditional Use
Lucas Fornari Laurindo, Sandra Maria Barbalho, Élen Landgraf Guiguer, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 739-739
Open Access | Times Cited: 70
Biological and neurological activities of astaxanthin (Review)
Pan Si, Chenkai Zhu
Molecular Medicine Reports (2022) Vol. 26, Iss. 4
Open Access | Times Cited: 69
Mitochondrial dysfunction in neurodegenerative disorders
Madelyn Klemmensen, Seth H. Borrowman, Colin Pearce, et al.
Neurotherapeutics (2023) Vol. 21, Iss. 1, pp. e00292-e00292
Open Access | Times Cited: 69
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification
Jeffrey L. Cummings, Amanda M. Leisgang Osse, Jefferson W. Kinney
Drugs (2023) Vol. 83, Iss. 15, pp. 1387-1408
Open Access | Times Cited: 64
Advances in Alzheimer’s disease’s pharmacological treatment
Carlos Elias Conti Filho, Lairane Bridi Loss, Clairton Marcolongo-Pereira, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 50
Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway
Zhaojun Wang, Xinru Li, Shi-Fan Chai, et al.
Neuropharmacology (2023) Vol. 240, pp. 109716-109716
Closed Access | Times Cited: 42
Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer’s disease with real-world clinical validation
Chao Yan, Monika E. Grabowska, Alyson L. Dickson, et al.
npj Digital Medicine (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 19
Obesity-induced inflammation: connecting the periphery to the brain
Ophélia Le Thuc, Cristina García‐Cáceres
Nature Metabolism (2024) Vol. 6, Iss. 7, pp. 1237-1252
Closed Access | Times Cited: 18
Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer’s model mice
So Yeon Cho, Eun Woo Kim, Soo Jin Park, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 17
Association between Mediterranean diet and dementia and Alzheimer disease: a systematic review with meta-analysis
Daniele Nucci, Andrea Sommariva, Luca Mario Degoni, et al.
Aging Clinical and Experimental Research (2024) Vol. 36, Iss. 1
Open Access | Times Cited: 17
Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US
William Yang Wang, QuangQiu Wang, Xin Qi, et al.
Alzheimer s & Dementia (2024)
Open Access | Times Cited: 16
Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Faizan Ahmad, Anik Karan, Rashi Sharma, et al.
Ageing Research Reviews (2024) Vol. 95, pp. 102229-102229
Closed Access | Times Cited: 15
Page 1 - Next Page

Scroll to top